Literature DB >> 30594097

Incidence, risk factors, and consequences of residual neuromuscular block in the United States: The prospective, observational, multicenter RECITE-US study.

Leif Saager1, Eric M Maiese2, Lori D Bash2, Tricia A Meyer3, Harold Minkowitz4, Scott Groudine5, Beverly K Philip6, Pedro Tanaka7, Tong Joo Gan8, Yiliam Rodriguez-Blanco9, Roy Soto10, Olaf Heisel11.   

Abstract

STUDY
OBJECTIVE: To determine the incidence burden and associated risk factors of residual neuromuscular block (rNMB) during routine U.S. hospital care.
DESIGN: Blinded multicenter cohort study.
SETTING: Operating and recovery rooms of ten community and academic U.S. hospitals. PATIENTS: Two-hundred fifty-five adults, ASA PS 1-3, underwent elective abdominal surgery with general anesthesia and ≥1 dose of non-depolarizing neuromuscular blocking agent (NMBA) for endotracheal intubation and/or maintenance of NMB between August 2012 and April 2013.
INTERVENTIONS: TOF measurements using acceleromyography were performed on patients already receiving routine anesthetic care for elective open or laparoscopic abdominal surgery. Measurements allowed assessment of the presence of residual neuromuscular block (rNMB), defined as a train-of-four (TOF) ratio <0.9 at tracheal extubation. We recorded patient and procedural characteristics and assessed TOF ratios (T4/T1) at various times throughout the procedure and at tracheal extubation. Differences in patient and clinical characteristics were compared using Fisher's exact test for categorical variables and t-test for continuous variables. Multivariate logistic regression assessed risk factors associated with rNMB at extubation. MAIN
RESULTS: Most of the study population, 64.7% (n = 165) had rNMB (TOF ratio < 0.9), among them, 31.0% with TOF ratio <0.6. Among those receiving neostigmine and/or qualitative peripheral nerve stimulation per clinical decision, 65.0% had rNMB. After controlling for confounders, we observed male gender (odds ratio: 2.60, P = 0.008), higher BMI (odds ratio: 1.04/unit, P = 0.043), and surgery at a community hospital (odds ratio: 3.15, P = 0.006) to be independently associated with increased odds of rNMB.
CONCLUSIONS: Assessing TOF ratios blinded to the care team, we found that the majority of patients (64.7%) in this study had rNMB at tracheal extubation, despite neostigmine administration and qualitative peripheral nerve stimulation used for routine clinical care. Qualitative neuromuscular monitoring and clinical judgement often fails to detect rNMB after neostigmine reversal with potential severe consequences to the patient. Our data suggests that clinical care could be improved by considering quantitative neuromuscular monitoring for routine care.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Delayed emergence from anesthesia; Neostigmine; Neuromuscular block; Neuromuscular monitoring; Train-of-four monitoring

Mesh:

Substances:

Year:  2018        PMID: 30594097     DOI: 10.1016/j.jclinane.2018.12.042

Source DB:  PubMed          Journal:  J Clin Anesth        ISSN: 0952-8180            Impact factor:   9.452


  12 in total

1.  Sugammadex versus Neostigmine for Reversal of Neuromuscular Blockade and Postoperative Pulmonary Complications (STRONGER): A Multicenter Matched Cohort Analysis.

Authors:  Sachin Kheterpal; Michelle T Vaughn; Timur Z Dubovoy; Nirav J Shah; Lori D Bash; Douglas A Colquhoun; Amy M Shanks; Michael R Mathis; Roy G Soto; Amit Bardia; Karsten Bartels; Patrick J McCormick; Robert B Schonberger; Leif Saager
Journal:  Anesthesiology       Date:  2020-06       Impact factor: 7.892

2.  A Clinical and Budgetary Impact Analysis of Introducing Sugammadex for Routine Reversal of Neuromuscular Blockade in a Hypothetical Cohort in the US.

Authors:  Yiling Jiang; Lori D Bash; Leif Saager
Journal:  Adv Ther       Date:  2021-04-19       Impact factor: 3.845

Review 3.  The latest trend in neuromuscular monitoring: return of the electromyography.

Authors:  Wonjin Lee
Journal:  Anesth Pain Med (Seoul)       Date:  2021-04-12

4.  A randomized-controlled trial of sugammadex versus neostigmine: impact on early postoperative strength.

Authors:  Ramon E Abola; Jamie Romeiser; Sabeen Rizwan; Brandon Lung; Ruchir Gupta; Elliott Bennett-Guerrero
Journal:  Can J Anaesth       Date:  2020-05-13       Impact factor: 5.063

5.  Utilization Patterns of Perioperative Neuromuscular Blockade Reversal in the United States: A Retrospective Observational Study From the Multicenter Perioperative Outcomes Group.

Authors:  Timur Z Dubovoy; Leif Saager; Nirav J Shah; Douglas A Colquhoun; Michael R Mathis; Steven Kapeles; Graciela Mentz; Sachin Kheterpal; Michelle T Vaughn
Journal:  Anesth Analg       Date:  2020-11       Impact factor: 6.627

6.  Association of neuromuscular reversal by sugammadex and neostigmine with 90-day mortality after non-cardiac surgery.

Authors:  Tak Kyu Oh; Jung-Hee Ryu; Sunwoo Nam; Ah-Young Oh
Journal:  BMC Anesthesiol       Date:  2020-02-20       Impact factor: 2.217

7.  Economic impact of improving patient safety using Sugammadex for routine reversal of neuromuscular blockade in Spain.

Authors:  J Martinez-Ubieto; C Aragón-Benedí; J de Pedro; L Cea-Calvo; A Morell; Y Jiang; S Cedillo; P Ramírez-Boix; A M Pascual-Bellosta
Journal:  BMC Anesthesiol       Date:  2021-02-16       Impact factor: 2.217

8.  Recovery of early postoperative muscle strength after deep neuromuscular block by means of ultrasonography with comparison of neostigmine versus sugammadex as reversal drugs: study protocol for a randomised controlled trial.

Authors:  Xuan Wang; Yingyuan Li; Chanyan Huang; Wei Xiong; Qin Zhou; Lijun Niu; Ying Xiao
Journal:  BMJ Open       Date:  2021-02-26       Impact factor: 2.692

9.  Peri-operative diaphragm ultrasound as a new method of recognizing post-operative residual curarization.

Authors:  Jiaxin Lang; Yuchao Liu; Yuelun Zhang; Yuguang Huang; Jie Yi
Journal:  BMC Anesthesiol       Date:  2021-11-19       Impact factor: 2.217

10.  Supine versus semi-Fowler's positions for tracheal extubation in abdominal surgery-a randomized clinical trial.

Authors:  Qiongfang Zhu; Zheyan Huang; Qiaomei Ma; Zehui Wu; Yubo Kang; Miaoyin Zhang; Tiantian Gan; Minxue Wang; Fei Huang
Journal:  BMC Anesthesiol       Date:  2020-08-01       Impact factor: 2.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.